Medco Research
Executive Summary
Bethanidine, an anti-arrhythmic agent, granted orphan drug designation by FDA for treatment of primary ventricular fibrillation. Los Angeles-based Medco, which acquired the drug from Robins, says it will begin clinical studies "shortly".